目的观察丹参多酚酸盐注射液治疗冠心病的临床疗效及安全性。方法 66例冠心病患者随机分为试验组32例和对照组34例,试验组静脉滴注丹参多酚酸盐200 mg+0.9%氯化钠注射液250 m L,每日1次,连续用药2周。对照组静脉滴注丹参注射液30 m L+0...目的观察丹参多酚酸盐注射液治疗冠心病的临床疗效及安全性。方法 66例冠心病患者随机分为试验组32例和对照组34例,试验组静脉滴注丹参多酚酸盐200 mg+0.9%氯化钠注射液250 m L,每日1次,连续用药2周。对照组静脉滴注丹参注射液30 m L+0.9%氯化钠注射液250 m L,每日1次,连续用药2周。比较2组治疗后总运动代谢量、运动诱发心绞痛的发作时间、运动诱发ST段压低1 mm的时间及心绞痛发作次数等指标变化情况、临床总有效率及不良反应发生情况。结果试验组总有效率为87.50%(28/32),显著高于对照组的61.76%(21/34),差异有统计学意义(P<0.05)。2组治疗前后总运动代谢量、运动诱发心绞痛的发作时间、运动诱发ST段压低1 mm的时间及心绞痛发作次数等指标比较,差异均有统计学意义(P<0.05)。试验组治疗后,硝酸甘油用量和心绞痛发作次数均显著少于对照组(P<0.05)。试验组不良反应总发生率为6.25%(2/32),对照组为8.82%(3/34),差异无统计学意义(P>0.05)。结论丹参多酚酸盐治疗冠心病临床疗效确切,可降低心绞痛发生次数,不良反应发生率低。展开更多
Objective:To investigate the alteration of plasma levels of omentin-1 and visfatin in elderly patients with coronary heart disease(CHD)and heart failure.Methods:Plasma omentin-1 and visfatin levels were measured in 90...Objective:To investigate the alteration of plasma levels of omentin-1 and visfatin in elderly patients with coronary heart disease(CHD)and heart failure.Methods:Plasma omentin-1 and visfatin levels were measured in 90 subjects(29 stable angina pectoris(SAP)cases,30 unstable angina pectoris(UAP)cases and 31 age-and sex-matched healthy controls(age≥60 years)by enzyme-linked immunosorbent assay methods.According to the New York Heart Association classification.59 CHDs were divided into three groups:functional I class,11 cases;functional II/III class,36 cases;and functional IV class,12 cases.Results:The plasma level of omentin-1in CHO patients was significantly lower than thai of the control group.Otnenlin-lin SAP group and UAP group were significantly lower compared to the control group(there was no statistical significance between UAP group and SAP group;P>0.05).The plasma level of visfatin in CHD patients was significandy higher than that of the control group.Similarly,visfatin in SAP group and UAP group were all significantly higher compared to the control group,while there was no statistical significance between UAP group,and SAP group.The plasma omentin-1 level was negatively correlated with SBP(r=-0.264,P<0.05),positively correlated with HDL-c level(r=0.271,P<0.05);the plasma visfatin level was positively correlated with TC(r=0.292,P<0.05),negatively correlated with HDL-c level(r=-0.266,P<0.05).There was a negative correlation between plasma omentin-1 and visfatin levels(r=-0.280,P<0.05).Moreover,multiple linear stepwise regression analysis showed that omentin-1 and visfatin levels might be affected by HDL-c level.Logistic regression analysis showed that visfatin could be an independent risk factor of CHD.Conclusions:Decreased levels of omentin-1 and increased levels of visfatin may be involved in the occurrence and development of CHD.Omentin-1 and visfatin,independently,may be protective and pro-inflammatory cytokines.Additionally,both omentin-1 and visfatin may be related to lipid metabolism.Visfatin may b展开更多
文摘目的观察丹参多酚酸盐注射液治疗冠心病的临床疗效及安全性。方法 66例冠心病患者随机分为试验组32例和对照组34例,试验组静脉滴注丹参多酚酸盐200 mg+0.9%氯化钠注射液250 m L,每日1次,连续用药2周。对照组静脉滴注丹参注射液30 m L+0.9%氯化钠注射液250 m L,每日1次,连续用药2周。比较2组治疗后总运动代谢量、运动诱发心绞痛的发作时间、运动诱发ST段压低1 mm的时间及心绞痛发作次数等指标变化情况、临床总有效率及不良反应发生情况。结果试验组总有效率为87.50%(28/32),显著高于对照组的61.76%(21/34),差异有统计学意义(P<0.05)。2组治疗前后总运动代谢量、运动诱发心绞痛的发作时间、运动诱发ST段压低1 mm的时间及心绞痛发作次数等指标比较,差异均有统计学意义(P<0.05)。试验组治疗后,硝酸甘油用量和心绞痛发作次数均显著少于对照组(P<0.05)。试验组不良反应总发生率为6.25%(2/32),对照组为8.82%(3/34),差异无统计学意义(P>0.05)。结论丹参多酚酸盐治疗冠心病临床疗效确切,可降低心绞痛发生次数,不良反应发生率低。
基金funded by the Natural Science Foundation of Hunan Province(No.12JJ5044)
文摘Objective:To investigate the alteration of plasma levels of omentin-1 and visfatin in elderly patients with coronary heart disease(CHD)and heart failure.Methods:Plasma omentin-1 and visfatin levels were measured in 90 subjects(29 stable angina pectoris(SAP)cases,30 unstable angina pectoris(UAP)cases and 31 age-and sex-matched healthy controls(age≥60 years)by enzyme-linked immunosorbent assay methods.According to the New York Heart Association classification.59 CHDs were divided into three groups:functional I class,11 cases;functional II/III class,36 cases;and functional IV class,12 cases.Results:The plasma level of omentin-1in CHO patients was significantly lower than thai of the control group.Otnenlin-lin SAP group and UAP group were significantly lower compared to the control group(there was no statistical significance between UAP group and SAP group;P>0.05).The plasma level of visfatin in CHD patients was significandy higher than that of the control group.Similarly,visfatin in SAP group and UAP group were all significantly higher compared to the control group,while there was no statistical significance between UAP group,and SAP group.The plasma omentin-1 level was negatively correlated with SBP(r=-0.264,P<0.05),positively correlated with HDL-c level(r=0.271,P<0.05);the plasma visfatin level was positively correlated with TC(r=0.292,P<0.05),negatively correlated with HDL-c level(r=-0.266,P<0.05).There was a negative correlation between plasma omentin-1 and visfatin levels(r=-0.280,P<0.05).Moreover,multiple linear stepwise regression analysis showed that omentin-1 and visfatin levels might be affected by HDL-c level.Logistic regression analysis showed that visfatin could be an independent risk factor of CHD.Conclusions:Decreased levels of omentin-1 and increased levels of visfatin may be involved in the occurrence and development of CHD.Omentin-1 and visfatin,independently,may be protective and pro-inflammatory cytokines.Additionally,both omentin-1 and visfatin may be related to lipid metabolism.Visfatin may b
